Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Rescriptor
Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents to treat human immunodeficiency virus type 1 (HIV-1) infection. It works by binding to and blocking the activity of reverse transcriptase, an enzyme essential for HIV replication. Delavirdine belongs to a class of medications called NNRTIs, which are known for their generally good tolerability but potential for drug interactions and the development of resistance. It is typically administered orally.
Used in combination with other antiretroviral agents to treat HIV-1 infection.
Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported with delavirdine. Discontinue delavirdine immediately if severe skin rash develops.
Outcome:
Decreased delavirdine levels, leading to potential treatment failure.
Mechanism:
Rifampin induces CYP3A4, the enzyme responsible for delavirdine metabolism.
Outcome:
Increased delavirdine levels.
Mechanism:
Clarithromycin inhibits CYP3A4.
Outcome:
Increased delavirdine absorption.
Mechanism:
Food enhances delavirdine absorption.
Most likely new formulation: Extended-release formulation (Year: Unlikely, <1% confidence)
Based on historical usage patterns and current research trends, there is a low (<5%) likelihood of delavirdine being withdrawn from the market in the next 5 years.
Antiretroviral, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Bis(heteroaryl)piperazine